ANDA 211564, held by Glenmark Generics. Dapagliflozin.
As of Nov 15, 2026, ANDA 211564 (Dapagliflozin), held by Glenmark Generics, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 2020 | Original application | Tentative approval |
| Dapagliflozin5MG · tablet;oral | Dapagliflozin | None (tentative approval) |
| Dapagliflozin10MG · tablet;oral | Dapagliflozin | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters